Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

Clinical trial NCT05493618 · WITHDRAWN

Trial details

NCT number: NCT05493618
Sponsor: Hackensack Meridian Health
Status: WITHDRAWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma, Refractory

Start date: 2022-12-01
Primary completion: 2025-11-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.